(0.22%) 5 143.00 points
(0.18%) 38 510 points
(0.31%) 17 901 points
(-0.35%) $83.56
(1.82%) $1.958
(0.16%) $2 350.90
(0.54%) $27.69
(0.89%) $930.35
(-0.07%) $0.934
(-0.17%) $11.01
(-0.18%) $0.799
(1.17%) $92.95
Live Chart Being Loaded With Signals
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Šios dienos apimtis | 7.09M |
Vidutinė apimtis | 7.51M |
Rinkos kapitalizacija | 17.70B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.342 ( 2023-09-11 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.81 |
ATR14 | HKD0.00800 (0.11%) |
Tūris Koreliacija
China Medical System Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
China Medical System Koreliacija - Valiuta/Žaliavos
China Medical System Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD8.01B |
Bruto pelnas: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2023 |
Pajamos: | HKD8.01B |
Bruto pelnas: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2022 |
Pajamos: | HKD9.15B |
Bruto pelnas: | HKD7.04B (76.89 %) |
EPS: | HKD1.330 |
FY | 2021 |
Pajamos: | HKD8.34B |
Bruto pelnas: | HKD6.25B (74.93 %) |
EPS: | HKD1.221 |
Financial Reports:
No articles found.
China Medical System Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.337 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.274 (N/A) |
HKD0.342 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00693 | 2011-03-22 |
Last Dividend | HKD0.342 | 2023-09-11 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | HKD3.99 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.6 | -- |
Div. Sustainability Score | 9.69 | |
Div.Growth Potential Score | 5.90 | |
Div. Directional Score | 7.80 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2362.HK | No Dividend Player | 2023-06-01 | Annually | 0 | 0.00% | |
1349.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
0393.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
6677.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
1899.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
0927.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0057.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
2883.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1480.HK | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.300 | 1.500 | 4.01 | 6.01 | [0 - 0.5] |
returnOnAssetsTTM | 0.135 | 1.200 | 5.49 | 6.58 | [0 - 0.3] |
returnOnEquityTTM | 0.152 | 1.500 | 9.42 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.567 | -1.000 | 4.33 | -4.33 | [0 - 1] |
currentRatioTTM | 4.29 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.85 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.10 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0734 | -1.500 | 8.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.50 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0839 | -1.500 | 9.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.758 | 1.000 | 0.696 | 0.696 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.339 | 1.000 | 5.23 | 5.23 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.923 | 1.000 | 0.429 | 0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.320 | -0.256 | [0.5 - 2] |
Total Score | 9.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 6.91 | 1.000 | 9.40 | 0 | [1 - 100] |
returnOnEquityTTM | 0.152 | 2.50 | 9.63 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.66 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 9.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.567 | 1.500 | 4.33 | -4.33 | [0 - 1] |
pegRatioTTM | 0.342 | 1.500 | -1.052 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.312 | 1.000 | 4.69 | 0 | [0.1 - 0.5] |
Total Score | 5.90 |
China Medical System
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.